Stem Cell Clinic

Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 – The Courier

The report for the worldwideAnimal Stem Cell Therapy marketgives a harsh thought regarding the various factors and patterns influencing the improvement graph of the worldwide market. Advancement of the effect of government strategies and guidelines on the activities in the Animal Stem Cell Therapy market is likewise referenced to offer a comprehensive synopsis of things to come viewpoint of the market. It presents refined development gauges for the Animal Stem Cell Therapy market based on dependable information and contains top to bottom information identified with the predominant elements of the market.

Likewise, the report additionally contains the significant parts in the Animal Stem Cell Therapy market.

Driving Industry Players:ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

You will discover total data with chapter by chapter list in this leaflet

You can contact our leader staff and get an example duplicate here:http://www.marketresearchstore.com/report/global-animal-stem-cell-therapy-market-report-2020-751651#RequestSample

Whats more in the report alongside significant player details?

The Animal Stem Cell Therapy market report analyzes the market dependent on market sections [Product Types:Dogs, Horses, Others;Product Applications:Veterinary Hospitals, Research Organizations] and significant geologies North America, Europe, Asia Pacific, Latin America, Middle East, Africa, and the rest of the world alongside present patterns on the lookout. The report has information of worldwide market that incorporates an enormous number of rumored associations, sellers, firms, and maker, and can offer a point by point layout of the general players who has a gigantic job as far as income, request, and deals through their solid administrations, post-deal cycles, and items.

Key boundaries that characterize the serious scene of the Global Animal Stem Cell Therapy Market:

The report is a point by point investigation of development drivers, restrictions, and the latest things. It includes itemized profiles of driving business sector players, the examination of late improvements in tech, and interesting model investigation. It offers market projections for the years to come. The report likewise contains an audit of large scale and miniature viewpoints significant for the new participants and current market players alongside the definite examination of the significant worth chain.

The Animal Stem Cell Therapy market report additionally offers a forward-looking perspective on different angles controlling or driving the development of the market. The Animal Stem Cell Therapy market report offers a pin-point examination for changing serious elements. It helps with realizing the significant item areas and their future. It offers a gauge assessed dependent on how the market is guage to create.

Peruse total Report with TOC:http://www.marketresearchstore.com/report/global-animal-stem-cell-therapy-market-report-2020-751651

Whats in store from the Global Animal Stem Cell Therapy Market report:

Centered Study on Strategy, Development and Perception Scenario

Global Top 10 Companies Share Analysis in Animal Stem Cell Therapy Market

Achieve vital experiences on contender data to grow ground-breaking R&D moves

Identify arising players and make viable counter-systems to cross the serious edge

Identify vital and different item types/administrations offering gave by significant players to Animal Stem Cell Therapy market development

Note:To give a more exact market figure, every one of our reports will be refreshed before conveyance considering the impacts of COVID-19.

About Us:

MarketResearchStore.comis a single destination for all the industry, company, and country reports. We feature a large repository of the latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact the US:

Joel John Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442 United States Toll Free: +1-855-465-4651 (USA-CANADA) Tel: +1-386-310-3803 Web:http://www.marketresearchstore.com Email:sales@marketresearchstore.com

See the rest here:
Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier

Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2025 – The Courier

The report named GlobalStem Cell Therapy Market2020 by Company, Regions, Type, and Application, Forecast to 2025 is a broad audit of the market size and patterns with values. The report is a thorough report on worldwide market investigation and experiences. The report is an arrangement of itemized market outline dependent on sorts, application, patterns and openings, consolidations and acquisitions, drivers and restrictions, and a world coming to. The report centers around the arising patterns in the worldwide and provincial spaces on all the huge segments, for example, market limit, cost, value, request and supply, creation, benefit, and serious scene. It offers a board translation of the worldwide Stem Cell Therapy industry from a scope of data that is gathered through respectable and checked sources.

NOTE:Our experts observing the circumstance across the globe clarifies that the market will create gainful possibilities for makers post COVID-19 emergency. The report means to give an extra outline of the most recent situation, financial stoppage, and COVID-19 effect on the general business.

Market Rundown:

The report investigates past patterns and future possibilities in this report which makes it exceptionally conceivable for the examination of the market. The report gives subtleties of the market by definitions, applications, market plot, item conclusions, and cost structures. The examination moreover shows the market contention scene and a relating point by point examination of the huge dealer/makers in the worldwide Stem Cell Therapy market. At that point, it presents another endeavor SWOT examination, adventure likelihood, and assessment. The report offers a figure assessment of the valuation of the market 2020-2025.

DOWNLOAD FREE SAMPLE REPORT:http://www.marketresearchstore.com/report/global-stem-cell-therapy-market-report-2020-industry-752969#RequestSample

The report talks about an entire attitude toward the difficulties existing among the business alongside the rising dangers, imperatives, and constraints. The report contains a full breakdown of the market elements like drivers, development possibilities, item portfolio, mechanical progressions, and a full investigation of the critical contenders of the market. The overall Stem Cell Therapy market is segmental into types, applications, innovation, end-clients, business verticals, and key geologies.

The central participants concentrated in the report include:Anterogen, Caladrius, RTI Surgical, BIOTIME, Osiris Therapeutics, Pharmicell, AlloSource, MEDIPOST, JCR Pharmaceuticals, BrainStorm Cell Therapeutics, Holostem Terapie Avanzate, Advanced Cell Technology, NuVasive

The main sorts of worldwide market items shrouded in this report are:Autologous, Allogeneic

The most generally utilized downstream fields of the worldwide market canvassed in this report are:Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Key areas and nations are canvassed in the worldwide Stem Cell Therapy market as follows: North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, and so forth), Middle East and Africa (Saudi Arabia, Egypt, Nigeria, and South Africa)

The report comprises of a summed up market study and in general insights about the business occasions to key partners to grow their business and catch incomes. The worldwide Stem Cell Therapy market report offers definite examination upheld by solid insights on special and income by players for the time frame 2015-2020. Different subtleties included are organization depiction, significant business, item presentation, ongoing turns of events, deals by area, type, application, and by deals channel.

ACCESS FULL REPORT:http://www.marketresearchstore.com/report/global-stem-cell-therapy-market-report-2020-industry-752969

Advance Information On The Market:

About Us:

MarketResearchStore.comis a single destination for all the industry, company, and country reports. We feature a large repository of the latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact the US:

Joel John Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442 United States Toll Free: +1-855-465-4651 (USA-CANADA) Tel: +1-386-310-3803 Web:http://www.marketresearchstore.com Email:sales@marketresearchstore.com

Here is the original post:
Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2025 - The Courier

Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart – NC State News

Injecting hydrogels containing stem cell or exosome therapeutics directly into the pericardial cavity could be a less invasive, less costly, and more effective means of treating cardiac injury, according to new research from North Carolina State University and the University of North Carolina at Chapel Hill.

Stem cell therapy holds promise as a way to treat cardiac injury, but delivering the therapy directly to the site of the injury and keeping it in place long enough to be effective are ongoing challenges. Even cardiac patches, which can be positioned directly over the site of the injury, have drawbacks in that they require invasive surgical methods for placement.

We wanted a less invasive way to get therapeutics to the injury site, says Ke Cheng, Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at NCStates Department of Molecular Biomedical Sciences and professor in the NCState/UNC-Chapel Hill Joint Department of Biomedical Engineering. Using the pericardial cavity as a natural mold could allow us to create cardiac patches at the site of injury from hydrogels containing therapeutics.

In a proof-of-concept study, Cheng and colleagues from NCState and UNC-Chapel Hill looked at two different types of hydrogels one naturally derived and one synthetic and two different stem cell-derived therapeutics in mouse and rat models of heart attack. The therapeutics were delivered via intrapericardial (iPC) injection.

Via fluorescent imaging the researchers were able to see that the hydrogel spread out to form a cardiac patch in the pericardial cavity. They also confirmed that the stem cell or exosome therapeutics can be released into the myocardium, leading to reduced cell death and improved cardiac function compared to animals in the group who received only the hydrogel without therapeutics.

The team then turned to a pig model to test the procedures safety and feasibility. They delivered the iPC injections using a minimally invasive procedure that required only two small incisions, then monitored the pigs for adverse effects. They found no breathing complications, pericardial inflammation, or changes in blood chemistry up to three days post-procedure.

Our hope is that this method of drug delivery to the heart will result in less invasive, less costly procedures with higher therapeutic efficacy, Cheng says. Our early results are promising the method is safe and generates a higher retention rate of therapeutics than those currently in use. Next we will perform additional preclinical studies in large animals to further test the safety and efficacy of this therapy, before we can start a clinical trial.

I anticipate in a clinical setting in the future, iPC injection could be performed with pericardial access similar to the LARIAT procedure. In that regard, only one small incision under local anesthesia is needed on the patients chest wall, says Dr. Joe Rossi, associate professor in the division of cardiology at UNC-Chapel Hill and co-author of the paper.

The research appears in Nature Communications and was supported by the National Institutes of Health and the American Heart Association. Dr. Thomas Caranasos, director of adult cardiac surgery at UNC-Chapel Hill, also contributed to the work.

-peake-

Note to editors: An abstract follows.

Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair

DOI: 10.1038/s41467-021-21682-7

Authors: Dashuai Zhu, Zhenhua Li, Ke Cheng, North Carolina State University; Thomas Caranasos, Joseph Rossi, University of North Carolina at Chapel Hill Published: March 3, 2021 in Nature Communications

Abstract: Cardiac patch is an effective way to deliver therapeutics to the heart. However, such procedures are normally invasive and difficult to perform. Here, we developed and tested a method to utilize the pericardial cavity as a natural mold for in situ cardiac patch formation after intrapericardial (iPC) injection of therapeutics in biocompatible hydrogels. In rodent models of myocardial infarction (MI), we demonstrated that iPC injection is an effective and safe method to deliver hydrogels containing induced pluripotent stem cells-derived cardiac progenitor cells (iPS-CPCs) or mesenchymal stem cells (MSCs)-derived exosomes. After injection, the hydrogels formed cardiac patch-like structure in the pericardial cavity, mitigating immune response and increasing the cardiac retention of the therapeutics. With robust cardiovascular regeneration and stimulation of epicardium-derived repair, the therapies mitigated cardiac remodeling and improved cardiac functions post MI. Furthermore, we demonstrated the feasibility of minimally-invasive iPC injection in a clinically-relevant porcine model as well as in human patients. Collectively, our study establishes iPC injection as a safe and effective method to deliver therapeutics to the heart for cardiac repair.

See original here:
Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart - NC State News

Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies – Technology Networks

Read Time:

Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neuron disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's.

When the nervous system is injured, diseased or infected, star-shaped cells, called astrocytes, undergo 'reactive' changes in their behaviour. Whilst some of these reactive astrocytes become protective, others become harmful and damage surrounding motor neurons.

Reactive astrocytes are observed in various neurodegenerative diseases including ALS, but there is a lack of understanding about what causes astrocytes to undergo this change.

In their research, published inNucleic Acids Researchtoday (4th March), the scientists compared ALS-diseased astrocytes with healthy astrocytes to uncover how the diseased cells become reactive. These cells were grown from human induced pluripotent stem cells - master stem cells - which can be directed to differentiate into any cell in the human body.

They found that key to the astrocyte change in diseased cells is an increase in the removal of introns (non-coding sections of genetic information) from RNA in a process called splicing. The team identified that in healthy astrocytes there are some RNAs that normally retain certain introns however in diseased cells these particular introns are spliced out.

This has dramatic consequences on the cell's actions as when these introns are cut out of RNA, the remaining exons (coding sections of genetic information) are used as a recipe for building proteins and some of these proteins play a role in the astrocytes changing.

Rickie Patani, senior author, group leader at the Crick, Professor at UCL's Queen Square Institute of Neurology and a consultant neurologist at the National Hospital for Neurology and Neurosurgery, says: "Understanding how astrocytes undergo this transformation is a really exciting step forward. It brings us closer to potentially being able to control and prevent astrocytes from becoming harmfully reactive. While there's still a long way to go, we're hopeful that developing such a treatment is possible and that it could even potentially be used across all neurological conditions in which an increase in reactive astrocytes is also documented, including Parkinson's and Alzheimer's."

ALS is a rapidly progressing degenerative disease. Patients commonly suffer loss of movement, speech and eventually the ability to breathe, and most people only live 3 to 5 years after diagnosis. There are currently no treatments that can meaningfully alter the prognosis.

But understanding key cellular changes associated with ALS could help develop new therapies to slow disease progression.

Oliver Ziff, lead author and clinical fellow at the Crick, UCL's Queen Square Institute of Neurology and a neurology registrar at the National Hospital for Neurology and Neurosurgery, says: "Our group have previously shown that splicing is decreased in ALS motor neurons, so when we found the opposite in ALS astrocytes we were intrigued. In fact, increased splicing is what we find in other immune cells when they become activated or angry. This raises the possibility that ALS astrocytes inflict a toxic immune insult on the nervous system and opens new therapeutic avenues for treating ALS."

The researchers will continue this work to further understand the molecular mechanisms involved when astrocytes become reactive with the ambition of developing an intervention that could be used by doctors to slow disease progression.

Reference: Ziff OJ, Taha DM, Crerar H, et al. Reactive astrocytes in ALS display diminished intron retention. Nucleic Acids Research. 2021;(gkab115). doi:10.1093/nar/gkab115

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to see the original:
Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies - Technology Networks

Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging – OncLive

Biologic aging is a complex process. There are several theories on why and how we age, and it is probable that none of them account for all the aspects. We are constantly exposed to both internal and external stimuli that, over time, facilitate the aging process. These stimuli include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction. These factors accelerate cellular senescencewhat is thought to be the critical factor in aging and has been shown to increase with age.1,2

Cellular senescence is a condition in which a cell has lost the ability to proliferate, and senescent cells increase in almost all organs and tissues as we age. Over time, these changes ultimately lead to the development of significant comorbidities and the cumulative functional deficits we acquire during aging. However, senescent cells are metabolically active and can produce cytokines and inflammatory proteinsthe senescence-associated secretory phenotypefurther accelerating aging and promoting malignancy. FIGURE 1 illustrates the effect of age and insults on senescence.

Accumulation of senescent cells is implicated as a cause of tissue reprogramming, osteoporosis, glaucoma, neurodegeneration, type 2 diabetes, changes in the microbiome, immune system dysfunction, dysfunctional tissue repair and fibrosis, and cancer.3 Recent data have shown the potential role of chemotherapy and radiation therapy in accelerating aging. Nowhere is chemotherapys effect in accelerating aging more apparent than in children and adolescents treated successfully for childhood malignancy.4 In these patients, by the time they reach aged 35 years, approximately 30% have the clinical phenotype of a person aged 65 years, as evidenced by dramatic increases in cardiac disease and new second malignancies.

At the University of North Carolina Lineberger Comprehensive Cancer Center, we have focused on the effects of chemotherapy and accelerated aging in cancer. To date, we have studied the effects of chemotherapy on childhood cancer, early breast cancer, and bone marrow transplantation. Our research has explored the role of p16INK4a expression, a robust marker of biologic aging, following on the work of Norman E. Ned Sharpless, MD, director of the National Cancer Institute. p16INK4a encodes for a protein that blocks cyclin-dependent kinase, analogous to the cyclin-dependent kinase inhibitors now used in breast cancer, including palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio), that prevent cells from entering the cell cycle.5 This leads to cellular senescence. In murine models, aging is associated with dramatic changes in p16INK4a expression in almost all organs over the animals lifespan.6 In human studies, p16INK4a expression is measured in T lymphocytes using a reverse transcription-polymerase chain reaction as a surrogate for aging in other tissues. Studies of p16INK4a expression using other immunohistochemistry methods suggest changes in T cells represent mirror changes in other tissue, and further research in this area is underway.

The change in p16INK4a with aging is not linear, and after 60 years, it appears to plateau for unclear reasons.7 It is possible that those older persons who would have had high levels of p16INK4a expression have already died of age-related illness such as cardiovascular disease, and current studies are addressing this issue.

The large dynamic range of p16INK4a expressionapproximately 10-fold over the human lifespanmakes it an ideal biomarker for study. In healthy children and adolescents, p16INK4a expression is low to undetectable, with high levels appearing in older persons. FIGURE 2 shows the effect of age on p16INK4a expression in 594 patients. These data give p16INK4a expression the potential to be an accurate predictor of cell senescence in an individual patient.

For example, if one hypothesizes that senescent cells are less likely to replicate to ameliorate the adverse effects of chemotherapy (ie, myelosuppression or mucositis), then investigators might be able to accurately predict between 2 patients of the same ageone with high p16INK4a expression and one with lowthat the patient with higher expression would have less cellular reserve and be more vulnerable to adverse effects. Studies are underway to determine if p16INK4a expression measured before treatment will prove to be a predictive marker of toxicity for currently used adjuvant chemotherapy regimens.

Investigators have examined several hundred patients with early breast cancer and a smaller number with childhood cancer and after bone marrow transplantation, and they have found that most chemotherapy regimens cause rapid and sustained increases in p16INK4a expression. Changes are seen shortly and dramatically after beginning chemotherapy, persist over time, and are irreversible.5,8,9 In adolescents and young adults treated with chemotherapy, significant increases in p16INK4a expression were associated with frailty and represented a 35-year acceleration in age among frail young adult cancer survivors. These data mimic what has been clinically noted in large study of adults who had childhood cancer: Approximately one-third of young adults and childhood cancer survivors aged 35 years have a disease phenotype of a person aged 65 years.4 Our group has also found that p16INK4a expression rose markedly in patients treated with allogeneic or autologous stem cell transplants for hematologic malignancies. These patients had a 2- to 3-fold increase in p16INK4a expression corresponding to 16 to 28 years of accelerated aging.10

We have noted similar findings in women with early-stage breast cancer. In patients treated with adjuvant or neoadjuvant chemotherapy, especially with anthracycline-based regimens (doxorubicin, cyclophosphamide, and taxanes with or without carboplatin), p16INK4a expression rose dramatically during chemotherapy and persisted during follow-up. On average, chemotherapy accelerated aging by approximately 17 years of life span, with acceleration of 23 to 27 years for those treated with anthracycline-based treatment.

Of note, docetaxel/cyclophosphamide regimens were associated with only 11 years of aging, and we found no evidence that anti-HER2 therapy affected p16INK4a expression. In these studies, accelerated aging due to chemotherapy represents estimates based on the trajectory of p16INK4a expression in normal patients over their lifespan. We are uncertain of the long-term implications of these changes. In our breast cancer studies, baseline p16INK4a expression was also associated with fatigue. In a recent unpublished analysis (Mitin N, et al), the difference between a patients baseline p16INK4a expression and a normal value for a patient of the same agethe p16 gapwas highly predictive of chemotherapy-induced peripheral neuropathy with taxane chemotherapy. We also found that baseline p16INK4a expression is a significant predictor of a p16 change, independent of age or chemotherapy type, with those patients having lower baseline p16INK4a expression being more likely to have greater changes with any chemotherapy regimen. The reasons for this are unclear, but patients of similar age with higher p16INK4a less ability to overcome tissue and organ damage. Not all chemotherapeutic agentsfor example, taxanes used as a single agentmay be associated with accelerated aging.11 More detailed studies of patients treated with different agents, including immunotherapeutic and other biologic therapies, and for different types of cancer are needed.

The long-term implications of changes in p16INK4a expression with chemotherapy are unknown, but our data suggest that higher levels may be indicators of frailty, a syndrome associate with increased comorbidity, poor quality of life, and shortened survival. p16INK4a expression has been associated with other diseases of aging, including cardiovascular disease, osteoporosis, and other common illnesses, and our chemotherapy-treated patients with accelerated aging may experience major problems 10 to 20 years after treatment, similar to young adults with cancer, and at a time when they are not likely to be followed by their oncologists.

However, these concerns should not mitigate the use of what has proven to be markedly effective treatment regimens that have dramatically improved overall survival in childhood cancer and breast cancer. It is too early to speculate, especially in breast cancer, whether nonanthracycline regimens with similar effectiveness to anthracyclines may be worth considering for patients with long life expectancy. The use of biomarkers in aging research, geroscience, is an exciting area of exploration, and p16INK4a expression is just one of the markers currently being studied.12 The implications of accelerated aging are being studied in other scenarios, and a broad range of studies are exploring interventions to ameliorate biological changes suggesting accelerated aging.

An excellent review of these issues and potential interventions is available13 and describes studies of exercise, diet and nutrition strategies, and senolytics. Learning about the effects of cancer treatment on aging is of major importance, as the clinical scenario of cancer is dominated by older adults who already may have a substantial comorbid illness at the time of diagnosis that might be accelerated by treatment. In children and young adults with cancer, learning how to assess and, in the future, intervene to prevent treatment-related accelerated aging is also a major need.

Read more:
Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging - OncLive